{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"}]}],"title":"Baseline Prevalence of ADAs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1"}]}],"title":"Incidence of Treatment Emergent ADAs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"434"}],"units":"Participants"}],"description":"Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab","groups":[{"description":"Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG000","title":"Atezolizumab Plus Nab-Paclitaxel"}],"paramType":"NUMBER","populationDescription":"The anti-drug antibodies (ADA)-evaluable population is defined as all patients treated with atezolizumab who have at least one post-baseline ADA result.","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 53 months","title":"Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}